Scheduled date for submitting quarterly report: November 14, 2022
Scheduled date for starting dividend payment: December 2, 2022
(Amounts rounded down to the nearest million yen)
1. Consolidated Results for the Six Months Ended September 30, 2022 (From April 1, 2022, to September 30, 2022)
(1) Consolidated Operating Results
(Percentage changes relative to previous corresponding period)
Net sales
Operating profit
Ordinary profit
Profit attributable to
owners of parent
Million yen
%
Million yen
%
Million yen
%
Million yen
%
Six months ended
49,093
(0.0)
777
-
1,171
309.8
1,242
921.1
September 30 2022
Six months ended
49,102
-
(68)
-
285
-
121
-
September 30 2021
(Note) Comprehensive income: Six months ended September 30, 2022: 2,084 million yen (-%),
Six months ended September 30, 2021: (117) million yen (- %)
Earnings per share (Basic)
Earnings per share (Diluted)
Yen
Yen
Six months ended September 30, 2022
21.69
-
Six months ended September 30, 2021
2.12
-
(2) Consolidated Financial Position
Total assets
Net assets
Equity ratio
Million yen
Million yen
%
As of September 30, 2022
175,461
124,735
71.1
As of March 31, 2022
171,924
124,507
72.4
(Note) Equity: As of September 30, 2022: 124,735 million yen, As of March 31, 2022: 124,507 million yen 2. Dividends
Annual dividends per share
(Record date)
End of the 1st
End of the 2nd
End of the 3rd
Year-end
Total
quarter
quarter
quarter
Yen
Yen
Yen
Yen
Yen
Fiscal year ended
-
20.00
-
32.00
52.00
March 31, 2022
Fiscal year ending
-
20.00
March 31, 2023
Fiscal year ending
March 31, 2023
-
32.00
52.00
(Forecast)
(Note) Revisions to the dividend forecast in the current quarter: None
3. Forecast of Consolidated for the Year Ending March 31, 2023 (From April 1, 2022, to March 31, 2023) (Percentage changes relative to previous corresponding period)
Net sales
Operating profit
Ordinary profit
Profit attributable to
Earnings
owners of parent
per share
Million yen
%
Million yen
%
Million yen
%
Million yen
%
Yen
Full year
112,000
6.1
5,500
9.8
6,000
7.7
4,500
14.4
78.53
(Note) Revisions to consolidated business forecast in the current quarter: Non
1
4. Other
(1) Changes in major subsidiaries during the period
(Change of specified subsidiaries associated with a change of the scope of consolidation): None
Application of special accounting methods in the preparation of quarterly financial statements : Yes
Changes in accounting policies, changes in accounting estimates and restatements
1)
Changes due to mandatory changes of accounting standards
: Yes
2) Changes other than 1)
: None
3)
Changes in accounting estimates
: None
4)
Restatements
: None
Number of shares issued (common stock)
Number of shares issued and outstanding at the end of the fiscal year (including treasury stock) As of September 30, 2022: 64,607,936 shares,
Fiscal year ended March 31 2022: 64,607,936 shares
Number of shares of treasury stock at the end of the fiscal year
As of September 30, 2022: 7,306,054 shares,
Fiscal year ended March 31 2022: 7,304,000 shares
Averaged number of shares of during the period As of September 30, 2022: 57,302,263 shares, As of September 30, 2021: 57,302,001 shares
This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.
Explanations about the appropriate use of the business forecasts and other noteworthy points.
These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.
(Methods for obtaining supplementary materials and content of financial results disclosure)
Supplementary materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
KYORIN Holdings Inc. published this content on 10 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 November 2022 08:41:04 UTC.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.